TORONTO, Feb. 7 /PRNewswire-FirstCall/ - Patheon (TSX:PTI.to - News) announced today the appointment of James C. Mullen as Patheon’s Chief Executive Officer, effective immediately. Mr. Mullen has also been appointed a director of Patheon’s Board of Directors effective today. Ramsey Frank, Patheon’s Chairman stated, “The Board of Directors is very pleased that Jim Mullen will be joining Patheon. Mr. Mullen’s extensive pharmaceutical manufacturing background and proven track record of driving growth and profitability give us confidence that, under his leadership, Patheon will be able to realize its full potential as an industry leader.”
Mr. Mullen was most recently with Biogen Idec, Inc., where he held the position of CEO and President for ten years. Biogen Idec was formed from the merger, led by Mr. Mullen, of Biogen, Inc. and Idec Pharmaceuticals, to form one of the world’s largest biotechnology companies. Prior to the merger, Mr. Mullen was the CEO and President of Biogen, Inc. from 2000 to 2002, and Chairman, CEO and President until 2003. Prior to that, Mr. Mullen held various operating positions at Biogen, including Vice President, Operations, and several manufacturing and engineering positions over a nine-year period at SmithKline Beckman, Inc.
Mr. Mullen’s 30-year career includes extensive experience in pharmaceutical and biotech manufacturing, engineering, sales, marketing, mergers and acquisitions. Mr. Mullen’s breadth of industry experience includes biotechnology, pharmaceuticals and specialty chemicals. Mr. Mullen holds a Bachelor of Science in Chemical Engineering from Rensselaer Polytechnic Institute, and a Master of Business Administration from Villanova University.
“The Board also wants to thank Peter Bigelow, Patheon’s President of North American Operations, for assuming the role of interim Chief Executive Officer while the search for the new CEO was conducted. His stewardship in this role over the last two months is greatly appreciated and we look forward to Peter’s continuing role as a key Patheon executive,” Mr. Frank stated.
ABOUT PATHEON
Patheon is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. It provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. The company uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Its comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic(TM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Its integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, ensures that customer products can be launched on-time and with confidence anywhere in the world.
